![FDA Panel Overwhelmingly Rejects MDMA Psychedelic as Mental Health Treatment](https://www.cchrint.org/wp-content/uploads/2024/06/ecstasy-fda-300x200.jpg)
FDA Panel Overwhelmingly Rejects MDMA Psychedelic as Mental Health Treatment
CCHR applauds the panel’s decision amid concerns over biased clinical trials and risks such as heart attacks, strokes, psychosis, and sexual abuse of patients during…
CCHR applauds the panel’s decision amid concerns over biased clinical trials and risks such as heart attacks, strokes, psychosis, and sexual abuse of patients during…
Mental health industry watchdog says tragic deaths linked to the hallucinogen ketamine spurs call for investigation into unregulated ketamine clinics and drug usage By CCHR…
By Jan Eastgate President CCHR International The Mental Health Industry Watchdog March 29, 2022 In a continuing series exposing the American Psychiatric Association’s updated Diagnostic and…
A banned device continues to be used to electroshock body parts of students for painful behavior modification & punishment and has human rights group riled….
By Kelly Patricia O’Meara January 7, 2016 The Food and Drug Administration (FDA) has initiated a proposal that would reclassify Electroconvulsive Therapy Devices (ECT) from…